210113-85-2

Basic information

• Product Name: Methyl 4-(2-aminoethoxy)benzoate hydrochloride
• Synonyms: methyl 4-(2-aminoethoxy)benzoate hydrochloride;210113-85-2;Methyl 4-(2-aminoethoxy)benzoate HCl;methyl 4-(2-aminoethoxy)benzoate;hydrochloride;SCHEMBL442778;YKKLMHVRCUIUIT-UHFFFAOYSA-N;MFCD16617505;CS-0259293;methyl4-(2-aminoethoxy)benzoatehydrochloride;EN300-72916;F88393;Methyl 4-(2-aminoethoxyl)benzoate hydrochloride;methyl 4-(2-amino-ethoxy)benzoate hydrochloride;4-(2-aminoethoxy)benzoic acid methyl ester hydrochloride;Z1473961797;4-(2-aminoethoxyl)benzoic acid methyl ester hydrochloride
• CAS NO: 210113-85-2
• Molecular Weight: 0
• Mol File: 210113-85-2.mol

Chemical Properties

• CAS DataBase Reference: Methyl 4-(2-aminoethoxy)benzoate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(2-aminoethoxy)benzoate hydrochloride(210113-85-2)
• EPA Substance Registry System: Methyl 4-(2-aminoethoxy)benzoate hydrochloride(210113-85-2)

Safety Data

• Hazardous Substances Data: 210113-85-2(Hazardous Substances Data)

Upstream product

• 99-76-3 methyl 4-hydroxylbenzoate 
• 26690-80-2 2-(N-tert-butoxycarbonylamino)ethanol 
• 67-56-1 methanol 
• 1050208-10-0 4-(2-aminoethoxy)benzoic acid hydrochloride 
• 174666-16-1 4-(2-tert-butoxycarbonylaminoethoxy)benzoic acid methyl ester 

Downstream Products

• 783356-68-3 abexinostat 

Relevant articles and documents

Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2AReceptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents

Adenosine is an immunosuppressive factor in the tumor microenvironment mainly through activation of the A2A adenosine receptor (A2AR), which is a mechanism hijacked by tumors to escape immune surveillance. Small-molecule A2AR antagonists are being evaluat

NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE

The present invention relates to compounds of the general formula: wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.

USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

The invention relates to the use of imidazole derivatives of the formula (I): in which A, R'1, R'2 and R'3 are as defined in the description, as AMPK activators. The invention also relates to processes for the preparation of the said compounds, to their uses for the preparation of medicaments for the treatment of insulin resistance, diabetes and related pathologies, and also obesity, and to the pharmaceutical compositions comprising them. Certain compounds of the formula (I) are novel and, in this respect, also form part of the invention.

Novel hydroxamates as therapeutic agents

The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes f

Method for treating glaucoma

Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma.

Prevention of loss and restoration of bone mass by certain prostaglandin agonists

Prostaglandin agonists of formula (I), in which, for example, A is a sulphonyl or acyl group, B is N or CH, M contains a ring and K and Q are linking groups, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits useful for the treatment of bone disorders including osteoporosis. STR1